Royalty Obligation and Deferred License Fees

3 Months Ended

Mar. 31, 2015

Royalty Obligation and Deferred License Fees [Abstract]

Royalty Obligation and Deferred License Fees

6. Royalty Obligation and Deferred License Fees

BioTime amortizes deferred license fees over the estimated useful lives of the licensed technologies or licensed research products. BioTime is applying a 10 year estimated useful life to the technologies and products that it is currently licensing. The estimation of the useful life of any technology or product involves a significant degree of inherent uncertainty, since the outcome of research and development or the commercial life a new product cannot be known with certainty at the time that the right to use the technology or product is acquired. BioTime will review its amortization schedules for impairments that might occur earlier than the original expected useful lives.

As of March 31, 2015, future amortization of deferred license fees described above was as follows:

Year Ended December 31,	Deferred License Fees
2015	$82,125
2016	109,500
2017	109,500
2018	73,667
2019	24,083
Thereafter	20,083
Total	$418,958

The current portion in the amount of $109,500 is included in prepaid expenses and other current assets. The noncurrent portion in the amount of $309,458 is included in deferred license and consulting fees.